X

Trial Profile

A Comparative study of efficacy and safety of Tapcom combination ophthalmic solution and Xalacom combination eye drops.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Mar 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tafluprost/timolol (Primary) ; Latanoprost/timolol
Indications Ocular hypertension; Open-angle glaucoma
Focus Therapeutic Use
Sponsors Santen Pharmaceutical

Most Recent Events

08 Mar 2019 Status changed from active, no longer recruiting to completed.
05 Jun 2018 Primary endpoint (IOP Change from baseline at the end of treatment) has not been met, as per the results published in the Advances in Therapy
05 Jun 2018 Results comparing the efficacy and safety published in the Advances in Therapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com